A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS

被引：84

作者：

Dunachie, SJ

Walther, M

Vuola, JM

Webster, DP

Keating, SM

Berthoud, T

Andrews, L

Bejon, P

Poulton, I

Butcher, G

Watkins, K

Sinden, RE

Leach, A

Moris, P

Tornieporth, N

Schneider, J

Dubovsky, F

Tierney, E

Williams, J

Heppner, DG

Gilbert, SC

Cohen, J

Hill, AVS

机构：

[1] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Nuffield Dept Med, Churchill Hosp, Oxford OX3 7LJ, England

[2] Imperial Coll London, London, England

[3] GlaxoSmithKline Biol, Rixensart, Belgium

[4] Oxxon Therapeut, Oxford, England

[5] PATH Malaria Vaccine Initiat, Bethesda, MD USA

[6] Walter Reed Army Inst Res, Malaria Vaccine Program, Silver Spring, MD USA

来源：

VACCINE | 2006年 / 24卷 / 15期

基金：

英国医学研究理事会; 英国惠康基金;

关键词：

T cells; malaria; clinical trial;

D O I：

10.1016/j.vaccine.2005.12.041

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Heterologous prime-boost immunisation with RTS,S/AS02A and the poxvirus MVA-CS was evaluated in 18 healthy malaria-naive subjects in Oxford. Both priming with RTS,S and boosting MVA-CS, and the reverse, were found to be safe and well tolerated. T cell responses as measured by IFN-gamma ex vivo ELISPOT were induced, but the responses were low to moderate in both groups, with heterologous boosting yielding only small increments in T cell immunogenicity and no increased antibody response. Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：2850 / 2859

页数：10

共 37 条

[1] Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific [J].

Alloueche, A ;

Milligan, P ;

Conway, DJ ;

Pinder, M ;

Bojang, K ;

Doherty, T ;

Tornieporth, N ;

Cohen, J ;

Greenwood, BM .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 68 (01) :97-101

[2] Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:: single-blind extended follow-up of a randomised controlled trial [J].

Alonso, PL ;

Sacarlal, J ;

Aponte, JJ ;

Leach, A ;

Macete, E ;

Aide, P ;

Sigauque, B ;

Milman, J ;

Mandomando, I ;

Bassat, Q ;

Guinovart, C ;

Espasa, M ;

Corachan, S ;

Lievens, M ;

Navia, MM ;

Dubois, MC ;

Menendez, C ;

Dubovsky, F ;

Cohen, J ;

Thompson, R ;

Ballou, WR .

LANCET, 2005, 366 (9502) :2012-2018

[3] Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].

Alonso, PL ;

Sacarlal, J ;

Aponte, JJ ;

Leach, A ;

Macete, E ;

Milman, J ;

Mandomando, I ;

Spiessens, B ;

Guinovart, C ;

Espasa, M ;

Bassat, Q ;

Aide, P ;

Ofori-Anyinam, O ;

Navia, MM ;

Corachan, S ;

Ceuppens, M ;

Dubois, MC ;

Demoitié, MA ;

Dubovsky, F ;

Menéndez, C ;

Tornieporth, N ;

Ballou, WR ;

Thompson, R ;

Cohen, J .

LANCET, 2004, 364 (9443) :1411-1420

[4] Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus [J].

Anderson, RJ ;

Hannan, CM ;

Gilbert, SC ;

Laidlaw, SM ;

Sheu, EG ;

Korten, S ;

Sinden, R ;

Butcher, GA ;

Skinner, MA ;

Hill, AVS .

JOURNAL OF IMMUNOLOGY, 2004, 172 (05) :3094-3100

[5] Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials [J].

Andrews, L ;

Andersen, RF ;

Webster, D ;

Dunachie, S ;

Walther, RM ;

Bejon, P ;

Hunt-Cooke, A ;

Bergson, G ;

Sanderson, F ;

Hill, AVS ;

Gilbert, SC .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2005, 73 (01) :191-198

[6] Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites [J].

Bejon, P ;

Andrews, L ;

Andersen, RF ;

Dunachie, S ;

Webster, D ;

Walther, M ;

Gilbert, SC ;

Peto, T ;

Hill, AVS .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (04) :619-626

[7] Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia:: a randomised trial [J].

Bojang, KA ;

Milligan, PJM ;

Pinder, M ;

Vigneron, L ;

Alloueche, A ;

Kester, KE ;

Ballou, WR ;

Conway, DJ ;

Reece, WHH ;

Gothard, P ;

Yamuah, L ;

Delchambre, M ;

Voss, G ;

Greenwood, BM ;

Hill, A ;

McAdam, KPWJ ;

Tornieporth, N ;

Cohen, JD ;

Doherty, T .

LANCET, 2001, 358 (9297) :1927-1934

[8] MALARIA TRANSMITTED TO HUMANS BY MOSQUITOS INFECTED FROM CULTURED PLASMODIUM-FALCIPARUM [J].

CHULAY, JD ;

SCHNEIDER, I ;

COSGRIFF, TM ;

HOFFMAN, SL ;

BALLOU, WR ;

QUAKYI, IA ;

CARTER, R ;

TROSPER, JH ;

HOCKMEYER, WT .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1986, 35 (01) :66-68

[9] A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in the Gambia [J].

Doherty, JF ;

Pinder, M ;

Tornieporth, N ;

Carton, C ;

Vigneron, L ;

Milligan, P ;

Ballou, WR ;

Holland, CA ;

Kester, KE ;

Voss, G ;

Momin, P ;

Greenwood, BM ;

McAdam, KPWJ ;

Cohen, J .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 61 (06) :865-868

[10] Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; Comparisons and combinations [J].

Gilbert, SC ;

Schneider, J ;

Plebanski, M ;

Hannan, CM ;

Blanchard, TJ ;

Smith, GL ;

Hill, AVS .

BIOLOGICAL CHEMISTRY, 1999, 380 (03) :299-303

← 1 2 3 4 →